

Potassium

Amandeep Khurana
Transplant Nephrologist
Southwest Kidney Institute

HOW MUCH POTASSIUM
IS IN YOU?

What is normal serum K?

- a. 2 meq/L
- b. 4 meq/L
- c. 6 meq/L
- d. 8 meq/L

normal serum K = 4 meq/L

normal ECF = 14L

normal extracellular K = 56 meq

What is normal intracellular K?

- a. 2 meq/L
- b. 4 meq/L
- c. 6 meq/L
- d. >8 meq/L

normal intracellular $K = 140 \text{ meq/L}$

normal ICF = 28L

normal intracellular $K = 3920 \text{ meq}$

HOW MUCH POTASSIUM IS IN YOU?

intracellular potassium: 3,920 mmol

extracellular potassium: 56 mmol

total body potassium: 3,976 mmol

HOW MUCH POTASSIUM IS IN YOU?

intracellular potassium: 3,920 mmol

extracellular potassium: 56 mmol

total body potassium: 3,976 mmol

1.4%


ALL your plasma has 12 meq of potassium.
What's the IOM recommended daily K intake?

- a. 10 meq
- b. 60 meq
- c. 100 meq
- d. 120 meq


POTASSIUM IS REGULATED BY THREE STEPS




Intake




Cellular Distribution




Renal Excretion






IOM recommended potassium intake = 120 meq/day





Dietary potassium intake is so large compared to plasma potassium, that if it didn't move intracellularly, lunch would be lethal



Cytosol

1
 1. Transporter binds 3 Na⁺ from cytosol.


2
 2. Phosphorylation by ATP favors conformational change.


3
 3. Na⁺ is released, K⁺ binds.


4
 4. Dephosphorylation favors original conformation.


5
 5. K⁺ is released to cytosol. Cycle can repeat.

Skeletal muscle cell










K K
K K K



Tzamaloukas AH, Ing TS, Elisaf MS, et al. Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports. *Int Urol Nephrol.* 2011;43(2):451-9.

STOOL LOSSES ARE 10 MMOL/DAY



THE REST IS RENAL LOSS

How does the kidney handle Na or glucose?

- a. Reabsorb 30-40% in each segment
- b. Reabsorb 80% proximally & fine tune distally
- c. Reabsorb 100% proximally & secrete distally


How does the kidney handle K?

- a. Reabsorb 30-40% in each segment
- b. Reabsorb 80% proximally & fine tune distally
- c. Reabsorb 100% proximally & secrete distally



Principal cells = K


A



Intercalated cells = H

B

How to secrete K



K secretion is determined by

1. Distal Na delivery + flow rate

2. Aldosterone: Increases number and activity of:

- Na-K ATPase

- ENaC


- K channel

Hyperkalemia


POTASSIUM IS REGULATED BY THREE STEPS



Intake



Cellular Distribution



Renal Excretion

BEFORE
UTE.




MORTON[®]

**SALT
SUBSTITUTE**

For Salt-Free Diets



NET WT. 3 1/8 OZ. (88.6g)



15 meq in ¼ teaspoon
60 meq in 1 teaspoon

Who is prescribed sodium restriction?

CHF
CKD
HYPERTENSION

What other medicines are they taking?

ACEI
ARB
ALDOSTERONE
ANTAGONISTS
BETA BLOCKERS


Unusual cause of hyperkalemia without renal failure:



Increased
I n t a k e

- Salt substitutes
- TPN
- Enteral supplements
- Blood transfusions
- High potassium foods
- Penicillin
- Dialysate





POTASSIUM CONTENT



Tomato Juice: 58 mmol/L


Noni Juice: 56 mmol/L

Orange Juice: 51 mmol/L


Pineapple Juice: 34 mmol/L




Intake



Cellular
Distribution





Renal
Excretion




Cellular Distribution


- Hyperosmolality
 - DKA and hyperglycemia
- Cell destruction
 - Rhabdomyolysis
 - Tumor lysis syndrome
- Drugs
 - Beta blockers
 - Digoxin
 - Succinylcholine
- Acidemia







K K
K K K



Tzamaloukas AH, Ing TS, Elisaf MS, et al. Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports. *Int Urol Nephrol.* 2011;43(2):451-9.


tissue destruction

trauma

tumor lysis syndrome


hypothermia

hemolysis



Copyright © 2007 Lippincott Williams & Wilkins.

Acidemia and potassium




H-K antiport
Does NOT exist


Figure 28. Multiple ion transport pathways directly or indirectly affect net K^+ flux in skeletal muscle cells. Reprinted with permission from Aronson PS, Giebisch G: Effects of pH on potassium: New explanations for old observations. *J Am Soc Nephrol* 22: 1981–1989, 2011.



Intake




Cellular
Distribution



Renal
Excretion

Decreased renal potassium excretion


- Renal failure
- Hypoaldosteronism
- Drugs
 - ACEi, ARB
 - NSAIDs
 - spironolactone
 - amiloride, triamterene
 - trimethoprim
- RTA 1 and 4
- Gordon's Syndrome (PHA)



Renal
Excretion

As a general rule, persistent hyperkalemia is always due to a failure of renal potassium handling

How to secrete K



K secretion is determined by

1. Distal Na delivery + flow rate

2. Aldosterone: Increases number and activity of:

Na-K ATPase

ENaC

K channels


- ROMK (Renal outer medullary K channel)
- Maxi-K/BK (Flow dependent)

Can ibuprofen cause hyperK?

- a. No
- b. Yes, because it's high in K
- c. Yes, because it decreases Na delivery
- d. Yes, because it blocks eNAC
- e. Yes, because it causes hypoaldosterism

Decreased Na delivery & flow rate

- Kidney failure
- NSAID
- Gordon's Syndrome (PHA II)



Can bactrim cause hyperK?

- a. No
- b. Yes, because it's high in K
- c. Yes, because it decreases Na delivery
- d. Yes, because it blocks eNAC
- e. Yes, because it causes hypoaldosterism


Blocking the eNaC causes hyperkalemia

Drugs

- Triamterene
- Amiloride
- Trimethoprim

Diseases

- Type 1 RTA
- Pseudohypoaldosteronism type 1




Can heparin cause hyperK?

- a. No
- b. Yes, because it's high in K
- c. Yes, because it decreases Na delivery
- d. Yes, because it blocks eNAC
- e. Yes, because it causes hypoaldosterism

Aldosterone increases

- eNaC
- Na-K-ATPase
- K channels
 - ROMK
 - Maxi-K/BK



Koeppen & Stanton: Berne and Levy Physiology, 6th Edition.
Copyright © 2008 by Mosby, an imprint of Elsevier, Inc. All rights reserved

Loss of aldosterone will
predictably increase
potassium

HYPOALDOSTERONISM


- Congenital
- Adrenal insufficiency (addison's disease)
- Diabetes
 - Hyporenin-hypoaldosterone
- Drugs:
 - ACEi/ARB/Renin inhibitors
 - Heparin
 - ketoconazole
- Competitive inhibition
 - spironolactone

the tubule's negative charge is the principle determinant of CCD potassium secretion

disrupted by chloride reabsorption

increased chloride reabsorption antagonizes potassium secretion


- Tacrolimus
- Cyclosporine



Koeppen & Stanton: Berne and Levy Physiology, 6th Edition.
Copyright © 2008 by Mosby, an imprint of Elsevier, Inc. All rights reserved

35 yr w/ CLL (WBC 150K) w/ $K = 6.5$.

You recheck $K = 3.5$. What's going on?

- 
- WBC over 100,000
 - Chronic lymphocytic leukemia (CLL)
 - Thrombocytosis
 - Tourniquets
 - Tube system
 - Cold weather


What's the main concern w/ hyperK?

- a. Irritability
- b. Muscle weakness
- c. EKG changes
- d. Arrhythmia

CONSEQUENCES OF HYPERKALEMIA

- muscle weakness/paralysis
- ECG changes and arrhythmia
 - Increased extracellular potassium reduces myocardial excitability, with depression of both pacemaking and conducting tissues.
 - Increasing potassium leads to suppression of the SA node and conduction by the AV node and His-Purkinje system.

ECG CHANGES



ities

the atria

ing

es and bradycardia

with junctional

e complex rhythm

TREATMENT

- Goal of therapy is to prevent arrhythmia
- Calcium stabilizes cardiac membranes

40 yr w/ HFrEF, normal Cr, no weakness/EKG changes, K 7

Is this an emergency?

- a. Yes
- b. No

40 yr w/ HFrEF, normal Cr, no weakness/EKG changes, K 7

What's the next step?

- a. Repeat K
- b. Give Ca
- c. Give albuterol/insulin
- d. Give Lasix/cation binders

Hyperkalemic emergency

1. Ca gluconate 1g IV X 1
2. Insulin (10 units regular insulin + 50 mL of 50% dextrose) → closely monitor glucose levels Q1hr x 6
3. Albuterol 10-20 mg by nebulization over 10 minutes
4. Remove K (Lasix/binder/dialysis)

40 yr w/ HFrEF, normal Cr,
weakness/EKG changes present, K 5

Is this an emergency?

a. Yes

b. No

40 yr w/ HFrEF, AKI, ongoing GI bleed,
no weakness/EKG changes present, K 6

Is this an emergency?


a. Yes

b. No

Hyperkalemic emergency

- a. Muscle weakness/EKG changes
- b. $K > 6.5$
- c. $K > 5.5 + \text{AKI/CKD4/ESRD} + K \text{ intake}$

- Digoxin antidote for dig toxicity (DigFAB)
- Albuterol
- Insulin



Foxglove


Digitalis

inhaled beta-agonists are effective




inhaled beta-agonists are effective

- 8 studies show this works
- 20 mg works better than 10 mg
- IV administration is no better than nebulized
- additive to insulin
- may be repeated after 2 hours




inhaled beta-agonists are effective




as is intravenous insulin

- give regular insulin intravenously rather than subcutaneously



but sodium bicarbonate is not



- diuretics
- fludrocortisone
- polystyrene resins
- dialysis



Diuretics

Increased sodium
delivery to the CCD

Increased sodium
reabsorption through
the eNaC

Enhanced negative
charge in the tubule

KAYEXALATE

Studies published were done in a world without dialysis. Patients were maintained for days with repetitive dosing. Not representative of single dose use we see now.

WARNINGS


Colonic Necrosis

- Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Kayexalate use.
- Do not use in patients who do not have normal bowel function. This includes postoperative patients who have not had a bowel movement post surgery.
- Do not use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction)
- Discontinue use in patients who develop constipation. Do not administer repeated doses in patients who have not passed a bowel movement.

SPS should **not** be given to the following patients because they may be at high risk for intestinal necrosis


- Postoperative patients
- Ileus or who are receiving opiates
- Large or small bowel obstruction
- Underlying bowel disease, eg, ulcerative colitis or Clostridium difficile colitis

zirconium silicate crystal



- steepest decline in serum potassium with ZS-9 occurred during the first four hours of therapy.



patiromer



Weir MR et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. DOI: 10.1056/NEJMoa1410853



Of course, dialysis always works!



40 yr w/ HFrEF, normal Cr, no weakness/EKG changes, K 5.7


Is this an emergency?

- a. Yes
- b. No

40 yr w/ HFrEF, normal Cr, no weakness/EKG changes, K 5.7

What's the next step?

- a. Give Ca
- b. Give albuterol/insulin
- c. Give cation binders
- d. low-potassium diet, loop or thiazide diuretics, or a reduction or cessation of ACEI/aldactone



Questions?